- Home
- LXEO vs CGEN Comparison
LXEO vs CGEN Comparison
Compare LXEO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- CGEN
- Stock Information
- Founded
- LXEO 2017
- CGEN 1993
- Country
- LXEO United States
- CGEN Israel
- Employees
- LXEO N/A
- CGEN N/A
- Industry
- LXEO
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXEO
- CGEN Health Care
- Exchange
- LXEO Nasdaq
- CGEN Nasdaq
- Market Cap
- LXEO 140.6M
- CGEN 135.6M
- IPO Year
- LXEO 2023
- CGEN 2000
- Fundamental
- Price
- LXEO $2.71
- CGEN $1.47
- Analyst Decision
- LXEO Strong Buy
- CGEN Strong Buy
- Analyst Count
- LXEO 5
- CGEN 1
- Target Price
- LXEO $22.20
- CGEN $4.00
- AVG Volume (30 Days)
- LXEO 1.4M
- CGEN 268.4K
- Earning Date
- LXEO 05-08-2025
- CGEN 05-19-2025
- Dividend Yield
- LXEO N/A
- CGEN N/A
- EPS Growth
- LXEO N/A
- CGEN N/A
- EPS
- LXEO N/A
- CGEN N/A
- Revenue
- LXEO N/A
- CGEN $27,864,000.00
- Revenue This Year
- LXEO N/A
- CGEN $11.81
- Revenue Next Year
- LXEO N/A
- CGEN $28.37
- P/E Ratio
- LXEO N/A
- CGEN N/A
- Revenue Growth
- LXEO N/A
- CGEN N/A
- 52 Week Low
- LXEO $1.45
- CGEN $1.13
- 52 Week High
- LXEO $19.50
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- LXEO 48.48
- CGEN 49.50
- Support Level
- LXEO $1.90
- CGEN $1.13
- Resistance Level
- LXEO $2.64
- CGEN $1.35
- Average True Range (ATR)
- LXEO 0.48
- CGEN 0.11
- MACD
- LXEO 0.02
- CGEN 0.03
- Stochastic Oscillator
- LXEO 51.43
- CGEN 85.00
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.